GLP-1 receptor agonists show promise for pediatric obesity but their effects on obesity-related sleep disorders like sleep apnea in children remain largely unstudied.
Evidence gap identifiedDespite growing use of GLP-1 drugs in pediatric obesity, virtually no data exist on whether they improve the serious sleep disorders — OSA and OHS — that accompany childhood obesity
What the researchers found
The review identifies obstructive sleep apnea (OSA) and obesity hypoventilation syndrome (OHS) as serious sleep-related comorbidities in obese children, often coexisting with insulin resistance, type 2 diabetes, hypertension, and non-alcoholic fatty liver disease.
GLP-1 receptor agonists are highlighted as a promising pharmacologic intervention for pediatric obesity, but the review concludes that their use in children remains constrained by limited data — particularly regarding their impact on sleep disorders. The authors emphasize that it is currently unclear whether GLP-1 agonist-induced weight loss translates into improvements in OSA, OHS, or related outcomes like cognitive function and psychosocial wellbeing in pediatric populations.
Why it matters
Pediatric obesity rates are rising globally, and sleep disorders in obese children have cascading effects on development, learning, and long-term cardiovascular health. As GLP-1 drugs begin to be used in children, understanding whether they improve sleep — not just weight — is essential for comprehensive pediatric care. This review highlights a significant evidence gap that could shape how these peptide drugs are prescribed and studied in children.
How the study worked
Narrative review synthesizing literature on pediatric obesity, its sleep-related comorbidities, and available treatment approaches including lifestyle interventions, GLP-1 receptor agonists, and bariatric surgery. The review examines global trends, academic performance impacts, and the role of multidisciplinary wellbeing clinics.
What this study cannot tell us
This is a narrative review without systematic search methodology or meta-analytic pooling. It does not present new data. The discussion of GLP-1 agonists in pediatrics is limited by the scarcity of published studies in this population. The review does not provide specific efficacy data for GLP-1 drugs in children or quantify their effects on sleep outcomes.
How to read the evidence
This is a narrative review that synthesizes existing literature on pediatric obesity, sleep disorders, and emerging pharmacotherapies. It does not include systematic search methods, quality assessments, or pooled data analysis. While it provides a useful clinical overview, it represents expert opinion-level evidence.
When this study was published
Published in 2025, this review is highly current and addresses the emerging application of GLP-1 drugs in pediatric populations — a rapidly evolving area where new clinical data may soon address the evidence gaps identified here.
The bigger picture
GLP-1 receptor agonists are rapidly expanding from adult diabetes and obesity into pediatric use, but the evidence base for children lags behind. Sleep apnea is one of the most impactful yet understudied consequences of childhood obesity. This review sits at the intersection of three major trends: the pediatric obesity epidemic, the GLP-1 revolution, and growing recognition that sleep health is fundamental to child development.
Questions still open
- Does GLP-1 agonist-induced weight loss in obese children lead to measurable improvements in sleep apnea severity?
- What is the optimal age to initiate GLP-1 pharmacotherapy in obese children with sleep-disordered breathing?
- How do the cognitive and developmental effects of improved sleep interact with GLP-1 treatment outcomes in pediatric obesity?
Common questions
Can GLP-1 drugs help children with obesity-related sleep problems?
Why is sleep apnea such a concern in obese children?
Read the original research
Multidisciplinary care of pediatric obesity and its impact on sleep: a review.
Frontiers in sleep, 4, 1634185
Citation
Inja, Ravali; Cielo, Christopher. (2025). Multidisciplinary care of pediatric obesity and its impact on sleep: a review.. Frontiers in sleep, 4, 1634185. https://doi.org/10.3389/frsle.2025.1634185